Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, April 2, 2019
[ 12:00 AM ] - United States, WOPRAI
Mon, April 1, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, March 29, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Alethia Young Maintained (ASND) at Buy with Decreased Target to $139 on, Mar 29th, 2019
Alethia Young of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $151 to $139 on, Mar 29th, 2019.
Alethia has made no other calls on ASND in the last 4 months.
There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Alethia's Rating of Hold.
This is the rating of the analyst that currently disagrees with Alethia
- Joseph Schwartz of "Leerink Swann" Upgraded from Hold to Buy and Increased Target to $90 on, Thursday, January 24th, 2019
